BitFrontier Capital Holdings, Inc. has entered into a binding Letter of Intent to acquire ERApeutics, LLC, the creator of the EVERMIND™ beverage platform, in a transaction valued at $4,000,000 through the issuance of 400,000,000 restricted common shares. This acquisition represents a strategic expansion into the cognitive health and wellness sector, with EVERMIND™ being a physician-formulated, plant-based protein shake designed to support brain health with both immediate and long-term benefits. The brand's shelf stability, scientific backing, and commercial readiness make it particularly valuable in the competitive functional beverage market.
The acquisition includes six proprietary nootropic and adaptogenic formulations, an established R&D pipeline, academic research, trademarks, and a fully integrated e-commerce platform available at https://thinkevermind.com. Dr. Jordan Balencic, CEO of BFCH, emphasized the strategic value of EVERMIND™, comparing its potential impact on cognitive health to that of Celsius in the metabolism space. This move follows the company's recent elimination of over $2 million in toxic convertible debt, which reduced total liabilities to under $94,000 and strengthened the balance sheet for growth initiatives.
The functional beverage market is experiencing significant growth, with recent investments by major players like Keurig Dr Pepper and Coca-Cola highlighting the sector's potential. EVERMIND™ positions BFCH to capitalize on this trend with a unique, brain-focused product line that differentiates it from general wellness beverages. The acquisition is expected to bolster BFCH's balance sheet by adding intellectual property-backed assets and aligns with the company's strategy for an OTCQB uplisting, marking a transition from legacy status to a growth-oriented platform.
The transaction is expected to close within 60 to 90 days, pending due diligence and final documentation. Upon completion, EVERMIND™ will operate as a wholly owned subsidiary of EVERMIND Labs, with potential for future spin-offs. This acquisition underscores BFCH's commitment to establishing a significant presence in the wellness and performance sectors, leveraging the growing consumer interest in scientifically-backed cognitive health products. For more details on the acquisition and BFCH's strategic direction, investors can view the pitch at https://evermindholdings.com/evermind-beverage/.
